Quoin Pharmaceuticals Ltd ADR (QNRX): Next-Year EPS Estimate 53.15%
As of 2026-09-01, Quoin Pharmaceuticals Ltd ADR (QNRX) has a next-year EPS growth estimate of 53.15%. Featured in 4 EPS revision reports, most recently on 2026-07-02.
On 2026-08-27, analyst consensus for QNRX's next-year EPS growth shifted from 50.81% to 53.15% — a positive change of 2.34 percentage points. The revised estimate has been sustained across 6 subsequent trading sessions. Current-year growth is projected at 55.96%.
What's Driving This
The primary driver is a sharp upward revision to next-year EPS growth estimates, with analysts raising the forecast from 63.86% to 53.03%—though this still marks a reduction, the current estimate of 53.15% reflects continued strength. Headlines around FDA conditional approval of the QYLEKI brand name for QRX003 and a constructive Type C meeting with the FDA support the product-launch narrative behind the revision. The stock’s rise has extended beyond the initial estimate change, indicating sustained momentum. No single earnings beat or guidance raise was cited, but regulatory progress appears to underpin the move.
Generated 2026-08-29 from news as of 2026-08-29
Current Snapshot
- Sector
- Healthcare
- Industry
- Biotechnology
- EPS growth next year
- 53.15%
- EPS growth this year
- 55.96%
- EPS next quarter (est)
- -$1.62
- Last price
- $6.22
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-09-01 | 53.15% | 55.96% | -$1.62 | $6.22 |
| 2026-08-31 | 53.15% | 55.96% | -$1.62 | $6.22 |
| 2026-08-30 | 53.15% | 55.96% | -$1.62 | $6.12 |
| 2026-08-29 | 53.15% | 55.96% | -$1.62 | $6.12 |
| 2026-08-28 | 53.15% | 55.96% | -$1.62 | $6.12 |
| 2026-08-27 | 53.15% | 55.96% | -$1.62 | $5.16 |
| 2026-08-26 | 50.81% | 58.06% | -$1.53 | $5.18 |
| 2026-08-25 | 50.81% | 58.06% | -$1.53 | $5.07 |
| 2026-08-24 | 50.81% | 58.06% | -$1.53 | $5.42 |
| 2026-08-23 | 50.81% | 58.06% | -$1.53 | $5.57 |
| 2026-08-21 | 50.81% | 58.06% | -$1.53 | $5.57 |
| 2026-08-20 | 53.03% | 56.08% | -$1.62 | $4.99 |
| 2026-08-19 | 53.03% | 56.08% | -$1.62 | $4.72 |
| 2026-08-18 | 53.03% | 56.08% | -$1.62 | $4.97 |
| 2026-08-17 | 53.03% | 56.08% | -$1.62 | $5.19 |
| 2026-08-16 | 63.86% | 55.97% | -$1.67 | $5.09 |
| 2026-08-14 | 54.80% | 57.09% | -$1.58 | $5.09 |
| 2026-08-13 | 54.84% | 57.06% | -$1.61 | $6.05 |
| 2026-08-12 | 54.84% | 57.06% | -$1.61 | $5.89 |
| 2026-08-11 | 54.84% | 57.06% | -$1.61 | $5.35 |
| 2026-08-10 | 54.84% | 57.06% | -$1.61 | $5.36 |
| 2026-08-09 | 54.84% | 57.06% | -$1.61 | $4.79 |
| 2026-08-07 | 54.84% | 57.06% | -$1.61 | $4.79 |
| 2026-08-06 | 54.84% | 57.06% | -$1.61 | $4.57 |
| 2026-08-05 | 54.84% | 57.06% | -$1.61 | $4.37 |
| 2026-08-04 | 54.84% | 57.06% | -$1.61 | $4.35 |
| 2026-08-03 | 54.84% | 57.06% | -$1.61 | $4.45 |
| 2026-08-02 | 54.84% | 57.06% | -$1.61 | $4.45 |
| 2026-07-31 | 54.84% | 57.06% | -$1.61 | $4.45 |
| 2026-07-30 | 54.84% | 57.06% | -$1.61 | $4.40 |
Reports Featuring QNRX
- 2026-07-02
Top Stock Gainers Driven by EPS Estimate Revisions: QNRX Up 40.9%, IOT Up 24% - July 2, 2026
- 2026-07-01
Top EPS Revision-Driven Movers: QNRX Surges +44.9% as NMAX Sees 376.9% Growth Estimate
- 2026-06-30
QNRX surges 48.9% as EPS revision signal precedes price breakout; HELP, ACMR also climb
- 2026-06-29
EPS Revision Bonanza: LILA +61%, HELP +47%, BDSX +42% Lead Surge
Recent News
- Quoin Pharmaceuticals Receives FDA Conditional Approval of QYLEKI as the Proposed Brand Name for QRX003 for Netherton SyndromeGlobeNewswire
- Quoin Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial ResultsGlobeNewswire
- Quoin Pharmaceuticals Provides Clinical and Regulatory Update from Constructive Type C Meeting with U.S. FDA for QRX003 in Netherton SyndromeGlobeNewswire
Screen Performance
Aggregate stats across all 2024 tickers our top-EPS-revision screen has flagged over the past 153 days.
- Median return since detection
- +1.8%
- % of tickers in the green
- 54%
- Median return on winners
- +20.3%
- Large revisions captured
- 1641
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Also Tracked by Our Screen
Frequently Asked Questions
What is Quoin Pharmaceuticals Ltd ADR's next-year EPS growth estimate?▾
As of 2026-09-01, Quoin Pharmaceuticals Ltd ADR (QNRX) has a next-year EPS growth estimate of 53.15%, based on analyst consensus.
When was the latest EPS estimate revision for QNRX?▾
The most recent revision occurred on 2026-08-27, when analysts adjusted the next-year EPS growth estimate from 50.81% to 53.15%.
What sector and industry does Quoin Pharmaceuticals Ltd ADR belong to?▾
Quoin Pharmaceuticals Ltd ADR operates in the Healthcare sector, specifically the Biotechnology industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. QNRX appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. Quoin Pharmaceuticals Ltd ADR (QNRX) appears here because it was detected by our daily top-EPS-revision-performer screen.